# NAD+ in cellular energy

> Cellular energy and NAD+ | NAD plus energy — NAD plus energy inside a cell: electron transfer, NAD-consuming enzymes, ageing mice and the reason I hesitate over a universal goal of raising NAD+.

Electron transfer is the beginning of the story. Enzymes that consume NAD+ make the supply question much more interesting.

## Electron transfer

The most persuasive thing about NAD+ is also the easiest thing to stretch too far. It [acts as an electron-carrying coenzyme in cellular redox reactions](https://pubmed.ncbi.nlm.nih.gov/26785480/). Redox is the chemical exchange of electrons. This gives NAD+ a direct role in metabolism, a much firmer starting point than a vague association with feeling lively.

I like the mechanical specificity of that role. A molecule has a job, reactions depend on it, and changing its availability can be investigated. Yet the review of [human precursor trials](https://pubmed.ncbi.nlm.nih.gov/41083806/) describes inconsistent translation into clinical outcomes. The cellular job and the intervention question sit at different scales. Both are worth taking seriously.

A useful account also has to allow for location. NAD+ production and cycling are [organised into cellular compartments and linked to metabolic signalling](https://pubmed.ncbi.nlm.nih.gov/20007326/). That makes a single, undifferentiated idea of the body's energy supply feel rather crude to me. The location of a change can matter as much as its direction.

## Enzymes that consume NAD+

NAD+ has another set of obligations. [Sirtuins, PARPs and CD38/CD157 compete for the NAD+ pool](https://pubmed.ncbi.nlm.nih.gov/33353981/). These are families of enzymes that use NAD+ in cellular processes; their names recur because an account of supply also needs an account of consumption.

That is the turn in the story I enjoy most. The question expands from how much NAD+ can be supplied to what happens to it after it arrives. The [review of NAD+ metabolism during ageing](https://pubmed.ncbi.nlm.nih.gov/33353981/) connects its availability with cellular processes and disease susceptibility across model organisms and humans. It presents restoration as a candidate strategy. The word candidate is doing useful work.

The [same review](https://pubmed.ncbi.nlm.nih.gov/33353981/) treats NAD+ as both a central coenzyme and a signalling substrate. I think that dual role deserves more space than it usually gets in a replenishment story. A cellular supply serves several processes, with consumption inside the cell helping to shape its availability.

![Two technicians working with culture dishes at a bright laboratory bench](images/cell-culture-bench.webp)

*An illustrative laboratory scene for the cellular work; it does not depict a named laboratory or an experiment from the papers.*

## CD38 in ageing mice

A particularly strong mechanistic example comes from [mice lacking CD38](https://pubmed.ncbi.nlm.nih.gov/27304511/). They were protected against the age-related fall in NAD+, with preservation of SIRT3 activity and improved mitochondrial function and metabolic health. The experiment connects an enzyme that consumes NAD+ with the availability of NAD+ and downstream function.

The experiment earns my admiration for its precision. Removing a particular enzyme gives the supply story a causal test, rather than merely observing that quantities change together. Its setting remains a mouse genetic experiment. It supports interest in NAD+ metabolism while leaving human supplementation as a separate question.

The later [human evidence review](https://pubmed.ncbi.nlm.nih.gov/41083806/) adds a complication to the ageing premise itself: consistent observations of age-related NAD+ decline come from a limited number of human studies, and tissue-specific data remain sparse. That narrower human record deserves room alongside the striking mouse result.

## NAD+ in cancer models

The cell benefiting from NAD+ matters too. In [BRAF-inhibitor-resistant melanoma cell lines and mouse xenografts](https://pubmed.ncbi.nlm.nih.gov/29309612/), resistant tumour cells increased the NAD+ biosynthetic enzyme NAMPT. Inhibiting NAMPT depleted NAD+ and ATP, and improved survival in the mice carrying the grafted tumours.

That experiment makes me distrust an indiscriminate goal of raising NAD+ everywhere. This is a concern about biological context, grounded in a tumour experiment. The study tested enzyme inhibition in cell lines and mice; it cannot calculate cancer risk from human supplementation. I am unwilling to turn that uncertainty into either a frightening prediction or a reassuring blanket statement. The biology is interesting precisely because the identity of the cell changes the question.

---

I follow published NAD+ research from cellular chemistry to physical performance here; NAD Plus Energy is an editorial site, not a business or a source of medical advice.